对B细胞非霍奇金淋巴瘤的双特异性抗体组合疗法
Khushali Jhaveri1, Aditi Saha2, Luis Miguel Juarez-Salcedo3
1Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
Expert opinion on biological therapy
|December 12, 2025
概括
双特异性抗体 (BsAbs) 为B细胞非霍奇金淋巴瘤 (B-NHL) 提供了一种新的免疫疗法. 这些药物显示出高疗效和可控的安全性,为CAR T细胞疗法提供了切实可行的替代方案.
科学领域:
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 双特异性抗体 (BsAbs) 是新兴的免疫疗法药物,向CD3和CD20,使T细胞对抗恶性B细胞.
- 经批准的BsAbs如epcoritamab,glofitamab和mosunetuzumab在积极和惰的B细胞非霍奇金淋巴瘤 (B-NHL) 中显示出显著的疗效.
- BsAbs为CAR T细胞疗法提供了一种现成的替代方案,有利于无法接受或无法获得细胞治疗的患者.
研究的目的:
- 在B-NHL治疗中提供双特异抗体的全面审查.
- 详细介绍BsAbs在复发/耐药DLBCL,FL和MCL中的关键研究和结果.
- 讨论新兴的组合策略和BsAbs在耐火性疾病中的潜力.
主要方法:
- 关键临床研究的审查涉及BsAbs在B-NHL.
- 对单剂结果和组合策略的分析.
- 检查低风险和耐火B-NHL子集中的BsAb潜力.
主要成果:
- BsAbs在攻击性和惰性B-NHL中表现出显著的有效性,具有可管理的安全性.
- 结合BsAbs与细胞毒剂,ADC和莱纳利多米德的组合策略正在调查中.
- BsAbs显示出解决历史上耐火B-NHL子集的希望.
结论:
- 在B-NHL治疗中,BsAbs代表了显著的进步,在可预测的安全性下实现了深度缓解.
- 门诊可行性和现成的可用性使BSAbs成为一个实用的治疗选择.
- 预计基于BsAb的疗法将成为B-NHL多种治疗线的基础.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.7K
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.2K
相关概念视频
01:31Hybridoma Technology
17.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.1K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K